hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Thrombocytopenia : The drug is contraindicated in patients with platelet counts of less than 100,000 per μL because no clinical experience exists regarding such patients. Chronic kidney disease : Eptifibatide undergoes kidney elimination. In such patients with chronic kidney disease where a glycoprotein IIb/IIIa inhibitor is likely to provide benefit, Abciximab (trade name: Reopro) is an alternative medication. Current bleeding tendencies or abnormally prolonged coagulation parameters observed within 30 days before starting therapy with eptifibatide is intended. Coagulation parameters such as ACT, aPTT, TT, and PT should be followed closely during therapy and afterwards. Allergy to eptifibatide and/or other ingredients. Severe, uncontrolled hypertension. Pregnancy : No experience exists. Pregnant patients should be treated only when clearly needed. Lactation : No human data exists. Breast-feeding should be avoided during treatment in order to prevent damage to the newborn. Geriatric patients : No differences in side effects compared with younger patients have been seen. Nevertheless, geriatric patients should be very closely observed for bleeding and other side-effects. Pediatric patients : Eptifibatide is not indicated in patients below 18 years of age, because no experience exists.
The balance would, at least theoretically, actually decrease in size with heating to compensate for the lengthening of the hairspring. Through careful adjustment of the placement of the balance screws (brass or gold screws placed in the rim of the balance), a watch could be adjusted to keep time the same at both hot (100 °F (38 °C)) and cold (32 °F (0 °C)) temperatures. Unfortunately, a watch so adjusted would run slow at temperatures between these two. The problem was completely solved through the use of special alloys for the balance and hairspring which were essentially immune to thermal expansion. Such an alloy is used in Hamilton's 992E and 992B. Isochronism was occasionally improved through the use of a stopworks, a system designed to only allow the mainspring to operate within its center (most consistent) range. The most common method of achieving isochronism is through the use of the Breguet overcoil, which places part of the outermost turn of the hairspring in a different plane from the rest of the spring. This allows the hairspring to "breathe" more evenly and symmetrically. Two types of overcoils are found - the gradual overcoil and the Z-Bend. The gradual overcoil is obtained by imposing two gradual twists to the hairspring, forming the rise to the second plane over half the circumference; and the Z-bend does this by imposing two kinks of complementary 45 degree angles, accomplishing a rise to the second plane in about three spring section heights. The second method is done for esthetic reasons and is much more difficult to perform.
There is interest in using microbial therapeutics for cancer treatment. Some bacteria naturally grow well in low-oxygen environments, which are common inside tumors. These bacteria can move into tumors, remain there longer than many conventional treatments, and deliver therapeutic effects directly at the tumor site. Researchers are studying both natural and engineered bacteria that may slow tumor growth, stimulate immune responses against cancer, or work alongside existing cancer therapies.
Sources: en.wikipedia.org
== Career == Aramwit's career started as a Formulator/Research Investigator at Pfizer Pharmaceutical Worldwide in the USA. She then served as the deputy director for International Affairs and Immigrant Workers at the Internal Security Operations Command in Thailand from April 2014 to 2017. Since then, she has been serving as the Acting Vice President on the President and Administrative Board, while concurrently holding the position of Director of Research Projects at Center of Excellence in Bioactive Resources for Innovative Clinical Applications (BRICA) and Dean of the Faculty of Pharmaceutical Sciences at the Department of Pharmacy Practice (PharmCU) at CU. Within these roles, she oversaw collaborations on nutritional supplements with Innobic (Asia) and TISTR, led skincare product development with CU Innovation Hub and UMI Deeptech, and contributed to StemAktiv's research, highlighting its potential in skincare and aging treatment with safe herbal extracts, while also overseeing CU's Faculty of Pharmaceutical Sciences signing an MOU with Mahidol University and another MOU with Degree Plus. In addition, she has been appointed as an adjunct professor in the Faculty of Pharmacy at the Silpakorn University in Thailand and a visiting professor at the Institute of Natural Medicine of the University of Toyama in Japan.
== Other uses == Adult Nurse Practitioner Aircraft Nuclear Propulsion Lee Airport, Annapolis, Maryland, US (IATA airport code and FAA location identifier "ANP") Angika language (ISO language code "anp") Absolut Null Punkt, a Japanese band featuring KK Null Anpao or Anp, the two-faced Lakota god of the dawn in Native American mythology Aviação Naval Portuguesa or Portuguese Naval Aviation
Serous acinar cells of the salivary glands, or more concisely, salivary serous cells, are cells that produce watery, enzyme-rich saliva. Together with salivary mucous cells, these cells secrete most of the fluid that becomes saliva. The term serous refers to the fact that the fluid produced is thin and watery like serum (blood plasma without clotting proteins).
== Cold CNO cycles == Under typical conditions found in stars, catalytic hydrogen burning by the CNO cycles is limited by proton captures. Specifically, the timescale for beta decay of the radioactive nuclei produced is faster than the timescale for fusion. Because of the long timescales involved, the cold CNO cycles convert hydrogen to helium slowly, allowing them to power stars in quiescent equilibrium for many years.
Sources: en.wikipedia.org
Bodybuilders may supplement their diets with protein for reasons of convenience, lower cost (relative to meat and fish products), ease of preparation, and to avoid the concurrent consumption of carbohydrates and fats. Additionally, some argue that bodybuilders, by virtue of their unique training and goals, require higher-than-average quantities of protein to support maximal muscle growth. While the recommended dietary allowance is much less, Harvard Medical School points out in Harvard Health Publishing that this RDA (recommended daily allowance) is “the minimum amount you need to keep from getting sick — not the specific amount you are supposed to eat every day.” Protein supplements are sold in ready-to-drink health shakes, bars, meal replacement products (see below), bites, oats, gels and powders. Protein powders are the most popular and may have flavoring added for palatability. The powder is usually mixed with water, milk or fruit juice and is generally consumed immediately before and after exercising or in place of a meal. The sources of protein are as follows and differ in protein quality depending on their amino acid profile and digestibility:
=== Counter-Strike: Malvinas === Counter-Strike: Malvinas is a custom Counter-Strike: Source map, developed and distributed by Argentine web hosting company Dattatec. The map was released worldwide on 4 March 2013. The game is set in Stanley, the capital of the Falkland Islands, and revolves around a group of Argentine special forces (portrayed as the counter-terrorist team) capturing the archipelago from British Royal Marines, who are portrayed as terrorists. The map is inspired by the 1982 Falklands War, in which an estimated 650 Argentine and 255 British servicemen died. The mod prompted strong controversy in the United Kingdom; Dattatec's website was targeted by British hackers on 27 March 2013.
Tin (50Sn) is the element with the greatest number of naturally abundant isotopes, 10. Seven, 114-120Sn, are theoretically stable, while the remaining three, 112Sn, 122Sn, and 124Sn, are potentially radioactive to double beta decay, but no decay has been observed. This is generally attributed to the fact that 50 is a "magic number" of protons. In addition, 32 unstable tin isotopes are known, including tin-100 (100Sn) and tin-132 (132Sn), which are both "doubly magic". The longest-lived of these is tin-126 (126Sn), with a half-life about 230,000 years; with all others less than a year and the majority under 20 minutes. The number of known metastable states is very large, including a long series of low-lying states in odd isotopes from 117 on, which gives two nuclides with a longer life than any ground-state radioisotope other than 126: 121mSn, half-life 43.9 years, and 119mSn, half-life 293.1 days.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.